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EDITORIAL
COVID-19 in Qatar: Ways forward in public health
and treatment
Edwin van Teijlingen1,3,*, Brijesh Sathian1,4, Padam Simkhada2,3,5, Indrajit Banerjee6
INTRODUCTION
The rapid and virulent spread of new corona virus
COVID-19 took many by surprise. It is a stark
reminder of our constant battle with nature.
COVID-19 has a diverse range of clinical presenta-
tions, and for individuals, the effects range from being
asymptomatic to having viral pneumonitis and death.
This editorial outlines (a) the underlying nature of
COVID-19; (b) key public health measures and
(c) some of the lessons learnt from other countries
around the world.
EPIDEMIOLOGY OF COVID-19 IN QATAR
For many people in Qatar, they only experience mild
and asymptomatic illness. A recent study suggested
that as many as 78% of people with coronavirus have
no symptoms. We also know that transmission rates
are high in pre-symptomatic individuals [1]. At the
time of writing (29/6/2020) Qatar had 94,413
confirmed cases of COVID-19 and 110 deaths.
Worldwide, the equivalent figures were over ten
million cases and half a million deaths [2]. Globally,
Qatar has the highest prevalence of 33,872 cases per
1 million population, with a mortality rate of 4 per
100,000 [3]. At the same time only a small proportion
of the population (3.4%) has been infected with




Coronaviruses (CoV) constitute a single-stranded
positive sense RNA genome of 26-32 kb length and
have an outer protein envelop and spiky spherical
surface [4]. Theviral genomeof theCoVencodes several
structural proteins that help in entering, replicating and
assembling virions in host cells, among them the spike
'protein S' is crucial for pathogenesis as it mediates
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attachment to host cells. A report of five patients
hospitalizedwithpneumonia inDecember2019showed
that the viral genome sequencing of these patients have
identified a novel strain of coronavirus [5].
To date there are four identified genera of coronavirus
including MERS (Middle East respiratory syndrome)
and SARS (severe acute respiratory syndromes) [6].
This virus shows 88% sequence homology with two
bat-derived SARS-like coronaviruses, and about 50%
sequence identity with MERS [7]. This new virus was
first named "SARS-CoV-2" by the International Virus
Classification Commission.
The fundamental role of the spike protein in infectivity
suggests that it is a potential target for vaccine
development, antibody-mediated blocking therapy
and development of antigen-based diagnostic tests.
In addition, some have suggested that multiplication
of the SARS-CoV-2 genome relies on the viral
RNA-dependent RNA polymerase which is another
probable target for the investigational nucleotide
analogue Remdesivir that has broad-spectrum
antiviral activity against RNA viruses [8]. Therefore,
the possible utilization of existing antiviral treatments
has many advantages in terms of safety and efficacy
to be administered as investigational drugs for novel
SARS-CoV-2 infection.
Testing can be for antibodies or for the virus itself
(viral or antigenic tests). The former is linked to
developing herd immunity, the latter would perhaps
be more appropriate for contact tracing.
PREVENTION AND PROPHYLAXIS
Prophylaxis
Currently there is no drug which is approved to be
prescribed as a preexposure prophylaxis for COVID-19.
Clinical trials on the antimalarial drugs hydroxycho-
loroquine or choloroquine and HIV protease inhibitors
are under investigation for prophylactic use. In April
2020 the Indian Council of Medical Research
recommended chemoprophylaxis with hydroxychlor-
oquine 400 mg taken twice on the first day followed
by 400 mg once a week for asymptomatic healthcare
workers in direct contact of confirmed or suspected
COVID-19 patients, and for asymptomatic household
contacts of confirmed cases. However Rathi et al.,
reminded us that the safety of these immunomodu-
lators in people at risk of COVID-19 has never been
evaluated [9].
Clinical trials and potential candidates of
future drugs for COVID-19
To date there is no treatment that has been proved
to be highly effective and safe against COVID-19.
However, a number of drugs have shown some
promising results in clinical trials such as: remdesivir,
chloroquine or hydroxychloroquine, combination of
lopinavir and ritonavir with or without interferon-
beta-1a, azithromycin and a variety of traditional
Chinese medicine products [10]. An open label
Phase III randomized multi-country clinical trial known
as "Solidarity trial of treatments for COVID-19
1. local standard of care plus injecon Remdesivir
daily infusion for 10 days.
2. local standard of care plus oral Lopinavir and 
Ritonavir twice daily for 14 days.
3. local standard of care plus oral Lopinavir and 
Ritonavir twice daily for 14 days with injecon 
Interferon beta-1a for 6 days.
4. local standard of care plus oral Chloroquine or 
hydroxychloroquine two oral loading doses, then 
orally twice daily for 10 days.
5. local standard therapy alone = control group.
Figure 1. Five arms in Solidarity trial.
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infection in hospitalized patients"
(ISRCTN83971151) has been initiated in April
2020 by the WHO and recruits patients across
100 countries including Qatar, see Figure 1
[11,12].
Remdesivir: (developed as GS-5734) It is a broad-
spectrum antiviral drug and it was found to be
effective in minimizing the lung damage in rhesus
monkeys from MERS [13]. Remdesivir is a prodrug it
gets converted to its active metabolite adenosine
triphosphate which acts by inhibiting the RNA
dependent RNA polymerase enzyme. It was found
that it interrupts with the chain termination in
Ebola virus. This drug was also found to be
promising for the treatment of human immunodefi-
ciency virus (HIV) type 1 and the hepatitis B virus
[14,15]. On May 1, 2020 the US FDA issued an
emergency use approval for remdesivir to treat
laboratory confirmed cases of COVID-19 in children
and adults and for patients with the severe form of
the disease [16,8].
In a double-blinded, randomized, placebo-controlled
trial of remdesivir on 1063 patients at a loading dose
of 200 mg on the first day which was followed by
100 mg daily for up to 9 additional days has shown
that it could shorten the recovery time in hospitalized
COVID-19 patients [17].
Hydroxychloroquine (ATC Code: P01BA02) and
Chloroquine (ATC Code: P01BA01): Chloroquine
is a blood schizonticide, acts on the erythrocytic
cycle of plasmodium species and has been used for
malaria, rheumatoid arthritis over decades. It has got
additional anti-inflammatory, immunomodulatory,
local irritant and local anaesthetic, minor smooth
muscle relaxant, antihistaminic and antiarrhythmic
properties. Hydroxychloroquine, is similar to chlor-
oquine but it is N-ethyl substituents of chloroquine.
Hydroxychloroquine is FDA approved for treating
lupus erythematosus [18,19]. An observational
study in New York City concluded that hydroxy-
chloroquine has not reduced intubation or death in
patients with COVID-19. [20] Hydroxychloroquine
and chloroquine are drugs which are extensively
undergoing clinical trials worldwide and are part of
the Solidarity trial, which was initiated by the WHO.
In June 2020, the hydroxychloroquine arm of the
Solidarity trial (Figure 1) was stopped as interim trial
results showed that it produced little reduction in
the mortality of hospitalized COVID-19 patients
when compared to standard care [21].
Lopinavir–Ritonavir (ATC Code: J05AR10):
Lopinavir–ritonavir are both protease inhibitors
used in the treatment of HIV. Lopinavir is structurally
similar to ritonavir but is more potent [22]. Both
antiretroviral drugs bind avidly with the SARS-CoV
3C-like protease (SARS-CoV 3CLpro) [23]. In a
randomized controlled trial published in New England
Journal of Medicine and conducted in China on
lopinavir and ritonavir on 199 COVID-19 patients, it
showed that there was no clinical benefit of the
combination of drugs but there were more adverse
effects e.g., nausea, vomiting and diarrhoea (Chinese
Clinical Trial Register number, ChiCTR2000029308)
[24].
Interferon beta-1a: (ATC Code: L03AB07) Is
found to be effective in the treatment of multiple
sclerosis [25]. Interferons are glycoprotein cytokines
produced by host cells in response to viral infections.
They have antiviral property and inhibit viruses in
multiple steps, namely, viral penetration, synthesis of
viral mRNA, assembly of viral particles and their
release, suppression of viral protein synthesis.
Interferon receptors are JAK-STAT tyrosine protein
kinase receptors which on activation migrate to the
nucleus and induce transcription of interferon-
induced-proteins which exert antiviral effects. In a
study conducted on MERS in Saudi Arabia, it was
found that remdesivir and interferon beta have
superior antiviral activity to lopinavir-ritonavir in vitro
[26]. Combination of lopinavir–ritonavir and Inter-
feron beta-1a was shown to be effective in patients
infected with SARS and MERS in a transgenic
humanized mouse model [27].
Other drugs which have shown promising results in
clinical trials for COVID-19 are dexamethasone,
azithromycin and fevipafavir.
Dexamethasone
Dexamethasone is a long acting corticosteroid with a
half-life of . 36 hours. It is a known drug used for
allergic reactions, cerebral oedema and shock. It was
found to be very effective in COVID-19 patients in
reducing mortality. The Recovery trial, which is one of
the world’s largest clinical trials has reported on June
16, 2020 that patients on dexamethasone 6 mg per
day for 10 days has dramatically reduced the
mortality in COVID-19 patients on ventilators. The
case fatality rate was reduced by 20%. The probable
mechanism by which dexamethasone is effective in
patients with COVID-19 is by immunosuppressant
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effects as an overactive immune system is manifested
in COVID-19 patients [28].
Azithromycin
Azithromycin is a macrolide antibiotic. The mechanism
of action against COVID-19 is still unknown.
According to Poschet et al., azithromycin may increase
the pH of endosomal cells preventing the entry,
replication and spread of the virus [29]. Azithromycin
also has anti-inflammatory and immunomodulatory
effects reducing the pro-inflammatory state induced
by COVID-19 [30–31]. A study on 1061 patients in
France has shown that a combination of azithromycin
and hydroxychloroquine is effective in COVID-19
treatment and is associated with a very low fatality
rate in patients [32].
Favipavir
It is a broad spectrum inhibitor of viral RNA
polymerase enzyme which is commonly used in the
treatment of arenaviruses, bunyaviruses and filo-
viruses found to be effective in COVID-19 patients in
mild to moderate symptoms of COVID-19 in India.
Recently, faviqavir was included in a phase 2 clinical
trial [NCT04434248]. In a non-randomized trial of
80 patients with COVID-19 in China there was a
reduction in the time to COVID-19 viral clearance in
patients treated with favipiravir compared with the
lopinavir-ritonavir combination [33].
COVID-19 AND QATAR’S HEALTH SYSTEM
Qatar followed the WHO’s global advice to all
countries in mid-March: "test, test, and test". Qatar
started testing early [34] and has now tested over
10% of its population. In terms of public health,
antibody tests are important in detecting infections in
people who are asymptomatic, and the more tests
that are conducted the easier it becomes to trace
(potentially) infected people to reduce transmission.
The Qatar Ministry of Public Health [35] developed a
framework for action identifying four key stages: (1)
Preparedness, not just of the health services; (2)
Surveillance and detection to ensure the earliest
diagnosis, support and surveillance to contain out-
breaks; (3) Response and containment to limit
COVID-19 spread and ensure health services can
provide high quality care to large numbers of severe
patients, and (4) Recovery and continuity, especially
mitigating socio-economic impacts, learn lessons and
enhance future response capabilities.
As the proportion of tested people is higher in Qatar
compared than in most other countries, so is the
proportion of asymptomatic cases testing positive in
the general population. The question is can Qatar
cope? Does it have the capacity to test just under 3
million people and do the contact tracing?
In terms of health facilities, key questions in the
'Response & Containment' stage must address the
following: Does Qatar have adequate bed capacity
especially to deal with people affected by COVID-19
who are in need of ventilators in ICU? What is the
availability of PPE (personal protective equipment) such
as aprons, gloves, surgical masks and eye protection?
In terms of its health system, Qatar’s Framework for
Action followed the 2016 WHO Guidelines on Core
Components of Infection Prevention and Control (IPC)
Programmes at the National and Acute Health Care
Facility Level [35]. Thus the Framework for Action
includes cross-cutting programmes, such as: (1)
Infection prevention and control in among frontline
health workers at risk, (2) Communication strategy,
and (3) Promoting COVID-19 research [36]. The
latter includes Qatar participating in the already
mentioned Solidarity trial [11–12].
STOPPING THE SPREAD OF COVID-19
In a global crisis there are both global and local factors
at play. One key local factor in Qatar is its large
migrant workers' population. Living and working
conditions of migrant workers, such as camps are
overcrowded. Qatar recognises the risk of infection in
migrant workers, in addition to the importance of
recording new cases of COVID-19 across the country.
Whilst new infections have also increased among
citizens and residents, as a result of contact with
infected family members, who had been infected at
work or family gatherings, suggests a lack of
compliance of precautionary measures (Figure 2),
especially physical distancing and staying at home.
The ministry reports that (most) newly infected cases
have been quarantined where they are receiving the
necessary medical care [37].
It is important that any health promotion advice and
regulations aremadeavailable in the key languages (such
as Hindi, Bangla, Nepali) languages of Qatar’s migrant
workers as many do not speak Arabic or (poor) English.
It is worthwhile asking the question: "What can Qatar
learn from countries where COVID-19 appeared
earlier". We highlight three examples below.
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The UK started with a public health strategy
referred to as 'flattening the epidemic curve'
(Figure 1) and in the process building up a population-
level 'herd immunity', while seeking to protect
high-risk groups and hoping of the appearance of a
vaccine and effective treatments in due course. This
strategy did not include testing people suspected of
having the virus but promotes self-isolation and
improved hygiene measures as a personal prevention
strategy.
India introduced a public health strategy based on
severe measures to restrict movement of people to
suppress the epidemic, a so-called lockdown. This
involved mass quarantine, travel restrictions, closures
of education establishments and workplaces, and so
on, but not testing and contact tracing. This strategy
is potentially better at preventing the spread of the
virus in the short term, but it is not sustainable and is
not easily tolerated for longer periods of time by many
'healthy' people.
South Korea acted fast in January 2020, having had
experience from recent outbreaks of MERS. It had a
strategy that involved a focus on testing and of
tracing contacts of infected people. Testing and
contact tracing is commonly used in other infectious
diseases, such as sexually transmitted infections
(STIs). Some countries did not prioritise testing to
detect infected people followed by tracing others
they had been in contact with, partly because it is less
effective than for example partner tracing in STIs as
COVID-19 can be transmitted by asymptomatic and
pre-symptomatic individuals, and partly because the
number of people a person with COVID-19 has
contact with in a day is typically much higher than
those related to sexual contacts.
REMOTE CARE THROUGH TELEHEALTH
The measures adopted internationally to curb the
spread of COVID-19 have led to significant changes in
how healthcare is accessed and provided. As face-to-
face consultations between healthcare workers and
patients pose a potential risk to both parties, remote
care and telehealth offer alternatives.
Telehealth (or telemedicine) means providing per-
sonalised healthcare over a distance [38], it includes
consultations and communication by phone, text
messages, email or other internet-based services
[39]. While telehealth has much to offer in the
provision of remote care to patients, accessing it may
prove a significant challenge to those most in need,
including older people, those from socio-economically
disadvantaged backgrounds, and those with physical
or learning disabilities.
COVID-19 AND PREGNANCY
At present, limited information is available for
pregnant women with COVID-19 in order to propose
best practices for specialized care. However, the
literature suggests that pregnant women with
COVID-19 infection may develop severe clinical
manifestations [40]. Therefore, surveillance systems
for pregnant COVID-19 patients are being established
to analyse the maternal and foetal outcomes. Also,
awareness about management of COVID-19 positive
pregnancies and prevention of neonatal infection is
important for healthcare professionals. Proper vigi-
lance and monitoring of the disease spread and rapid
implementation of preventive measures are crucial to
contain the spread of infection in the community.
Readily available standard respiratory support to
1. All cizens/residents to install tracing app ‘Ehteraz’.
2. Max 2 people in one vehicle (3 for some excepons). 
3. Some sport allowed in areas close to residence, but 
with social distancing and face masks and avoiding 
gatherings from 19 May. 
4. Closing shops and commercial acvies 19-30 May, 
except food and catering shops, pharmacies and 
restaurant deliveries.
Figure 2. Qatar Public Health rules around COVID-19.
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manage severe COVID-19 infections in pregnancy is
crucial and should be implemented rigorously by a
multidisciplinary team. For better understanding, it is
essential to help provide systematic data reporting for
evidence-based clinical assessment, management and
pregnancy outcomes in infected females that will
guide healthcare facilities with limited resources to
manage this vulnerable population in such an
outbreak.
COVID-19 AND COMMUNITY HEALTH
Quarantine, hand hygiene, and face masks can
potentially minimize the infection rate and mortality
in the community [41]. TheQatari measures in Figure 2
need community participation, which is essential for a
collective and socially acceptable response to pre-
venting COVID-19. Engagement of local communities
is essential to ensure compliance of lockdown until
necessary measures are in place to ease the
restrictions. In addition, there is a need for tailored
national, regional, and community-based solutions for
infection prevention taking into consideration the
needs of our diverse population.
CONCLUDING REMARKS
There are direct effects of COVID-19 on individuals
infected by the virus and their families and friends,
and there are indirect effects related to public
health measures introduced to deal with the virus.
The latter refers particularly to restrictions on
movement of people due to quarantine and
lockdown, which can affect individuals and the
society in various ways. These will be key issues to
address when Qatar moves to a recovery state
post-COVID-19.
The rapid spread of COVID-19 is a sign of our
globalised world. It is the new reality of public health,
there will likely be variants or different corona-type
viruses in the future. We have learnt several things
already. First, at least 60% of the population has to
get infected to achieve herd immunity, no country
including Qatar has come near this proportion.
Second, appropriate public health measures will only
work with community involvement. Third, the health
and well-being of migrant workers need to be
considered as COVID-19 can easily spread in crowded
work places and living quarters. Fourth, telemedicine
can offer an opportunity for patients to consult health
workers without being physically close. Fifth, we all
need to be prepared for the population’s mental health
in the aftermath of COVID-19 and during its
lockdown. Last, but not least, we need to be prepared
for a second wave of COVID-19.
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